Chapter title |
Production of Full-Length Antibody by Pichia pastoris
|
---|---|
Chapter number | 3 |
Book title |
Recombinant Glycoprotein Production
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7312-5_3 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7311-8, 978-1-4939-7312-5
|
Authors |
Adam Nylen, Ming-Tang Chen |
Abstract |
The methylotrophic yeast Pichia pastoris has become an increasingly popular host for recombinant protein expression in recent times. MRL pioneered a glycoengineered humanized P. pastoris expression system that could produce glycoproteins with glycosylation profiles similar to mammalian systems. Therapeutic glycoproteins produced by the humanized P. pastoris platform have shown comparable folding, stability, and in vitro and in vivo efficacies in preclinical models to their counterparts produced from the CHO cells. P. pastoris offers a cost and time efficient alternative platform for therapeutic protein production. This chapter describes a protocol for using P. pastoris to produce full-length monoclonal antibodies. It covers a broad spectrum of antibody expression technologies in P. pastoris, including expression vector construction, yeast transformation, high-throughput strain selection, fermentation, and antibody purification. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 41 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 17% |
Student > Ph. D. Student | 6 | 15% |
Researcher | 4 | 10% |
Student > Master | 3 | 7% |
Professor > Associate Professor | 2 | 5% |
Other | 3 | 7% |
Unknown | 16 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 8 | 20% |
Agricultural and Biological Sciences | 5 | 12% |
Chemical Engineering | 3 | 7% |
Medicine and Dentistry | 3 | 7% |
Engineering | 3 | 7% |
Other | 2 | 5% |
Unknown | 17 | 41% |